Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection

[1]  Ching-Lung Lai,et al.  Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B , 2010, Hepatology.

[2]  Y. Imai,et al.  Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B , 2009, Journal of Gastroenterology.

[3]  T. Wilt,et al.  Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference , 2009, Annals of Internal Medicine.

[4]  Y. Liaw.  Natural history of chronic hepatitis B virus infection and long‐term outcome under treatment , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[5]  M. Kudo,et al.  Epidemiology of Hepatocellular Carcinoma in Japan and Korea , 2008, Oncology.

[6]  K. Tsoi,et al.  Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma , 2008, Alimentary pharmacology & therapeutics.

[7]  V. Wong,et al.  High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Hadziyannis,et al.  Adding‐on versus switching‐to adefovir therapy in lamivudine‐resistant HBeAg‐negative chronic hepatitis B , 2007, Hepatology.

[9]  B. McMahon,et al.  Chronic hepatitis B. , 2002, The New England journal of medicine.

[10]  P. Loehrer,et al.  Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .

[11]  M. Makuuchi,et al.  Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. , 2006, Gastroenterology.

[12]  E. Hatano,et al.  Implication of Frequent Local Ablation Therapy for Intrahepatic Recurrence in Prolonged Survival of Patients With Hepatocellular Carcinoma Undergoing Hepatic Resection: An Analysis of 610 Patients Over 16 Years Old , 2006, Annals of surgery.

[13]  C. Chu,et al.  Hepatitis B virus-related cirrhosis: natural history and treatment. , 2006, Seminars in liver disease.

[14]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[15]  Y. Sakamoto,et al.  A long‐term follow‐up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy , 2005, Cancer.

[16]  K. Tanikawa,et al.  Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[17]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[18]  Pietro Andreone,et al.  Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.

[19]  M. Daikoku,et al.  [Lamivudine therapy for chronic hepatitis B]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[20]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[21]  S. Mboup,et al.  Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers , 2004, Journal of medical virology.

[22]  V. Wong,et al.  236 Genotype C hepatitis B virus infection is associated with increased risk of hepatocellular carcinoma. A prospective cohort study , 2004 .

[23]  William M. Lee,et al.  Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.

[24]  N. Ogata,et al.  The long-term clinical outcome of 1-year treatment of chronic hepatitis B with lamivudine-5 years observation. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[25]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[26]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .

[27]  E. Tanaka,et al.  Hepatitis C virus and hepatocellular carcinoma. , 1998, Current studies in hematology and blood transfusion.

[28]  Chien-Jen Chen,et al.  Epidemiological characteristics and risk factors of hepatocellular carcinoma , 1997, Journal of gastroenterology and hepatology.

[29]  E. Schiff,et al.  A preliminary trial of lamivudine for chronic hepatitis B infection. , 1995, The New England journal of medicine.

[30]  R. Beasley.  Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.